




Business Plan Open Source Pharma – Inspire2Live (CONCEPT)

(An Inspire2go project initiated by Inspire2Live)

Goal

Open-Source Pharma (OSP) aims to change the paradigm of drug discovery and patient treatment, from the classic drug-centric protocol-driven way, to a patient centric and outcome driven approach.




Concerns and obstacles

The classic process is becoming increasingly expensive, non-transparent, inefficient and fragmented. Furthermore, it fails to keep up with the advances made in science and technology for the systematic delivery of optimal care to each patient (precision and personalized medicine).

Solution

Open-source Pharma - Inspire2Live is a patient and outcome driven approach to drug discovery and patient treatment. The proposition of OSP rests on the following pillars:

- **Patient driven drug development:** each patient's cancer is a unique point of departure mapped and guided by the state-of-the-art science and technology in precision medicine.
 - **Primary treatment:** The treatment that comes out of the diagnostic tools, drug-screening and data analysis is the first treatment for this patient and not given after the standard protocol. The patient involved has given her consent for this.
- **Precision Medicine:** diagnostics including innovations like Whole Genome Sequencing (WGS), RNA sequencing and Liquid Biopsy, artificial intelligence, organoids/tumoroids, organ on a chip and drug screening.
 - **All registered medicines** are in scope when the treatment is defined, not only the ones that are registered for this specific type of cancer. Later we will include phase2 medicines.
- **Disease Targets:** ultimately, all advanced cancer patients should be treated in this manner, but the OSP project scope will start with patients with three indications for which there are no good options and patients face imminent death, namely; cancer of unknown primary tumor (CUP), glioblastoma and pancreatic cancer.



Why now?

Science and technology in healthcare and particularly in precision medicine, have reached a point in which precision and personalized medicine have become a real possibility for patients. The classic drug-centric protocol-driven way is less flexible and is therefore only one of the many options within a personalized approach to treatment decision making. Not an alternative.

Where do we stand?

The concept is complete and stable. At this very moment we are approaching our partners in the medical and scientific realm as well as our potential funders and business partners.

If you would like to learn more or get involved please reach out to Piarella Peralta and Tielo Jongmans.